You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖-B(02696.HK)就HLX02與MABXIENCE訂立獨家許可協議
格隆匯 03-31 20:59

格隆匯3月31日丨復宏漢霖-B(02696.HK)公佈,公司已於2020年3月31日與Mabxience Research, S.L.訂立獨家許可協議,據此,公司同意授予Mabxience在阿根廷、烏拉圭及巴拉圭就腫瘤治療開發和商業化HLX02產品的獨家許可。於簽署獨家許可協議後,訂約雙方擬進一步鞏固業務關係,適時探索其他合作機會。

公司將收取首次簽約款項25萬美元,並於向阿根廷國家藥品、食品及醫療器械管理局提交阿根廷灌裝及封裝產品申請及許可產品於阿根廷首次商業銷售後收取里程碑款項50萬美元。

據悉,Mabxience是Insud Pharma旗下的一家全球性生物技術公司,在研發、生產和銷售生物類似藥單克隆抗體方面擁有十年的經驗。 Mabxience致力於為更多的需要高成本藥物的患者提供優質治療,為醫療系統做出可持續性的貢獻。Mabxience擁有三處研發及生產場所,一處位於西班牙,兩處位於阿根廷。Mabxience於2014年12月推出首款生物類似藥利妥昔單抗,該藥現已在全球多個市場獲批並分銷。 Mabxience的第二款產品貝伐珠單抗也於2016年11月在其首個市場推出。

HLX02為公司自主研發的單克隆抗體生物類似藥,主要用於治療HER2陽性的早期乳腺癌、HER2陽性的轉移性乳腺癌及HER2陽性的轉移性胃癌。截至本公告日期,公司已與多個合作伙伴(包括Accord、雅各臣藥業(香港)有限公司和Cipla Limited)訂立許可和商業化協議,以便成功於中國境外進行HLX02的商業化,包括中國香港、中國澳門、馬來西亞、澳洲、紐西蘭、哥倫比亞,以及歐洲、中東-北非及獨聯體70多個司法權區及地區。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account